A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2018
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Ixabepilone (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 29 Oct 2018 Planned End Date changed from 1 Mar 2022 to 1 Feb 2026.
- 29 Oct 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Feb 2021.
- 31 Aug 2018 Biomarkers information updated